The claim arrived tonight in title case on a Timcast video: "IT WILL CURE BLINDNESS," roughly 32,000 views as of our Monday evening sweep. The document underneath it carries two datelines, and the pair is most of the story. GEG Tech's own news page for the research is dated, in its own words, "January 20th, 2025" [1]. The identical release ran August 5, 2026 in the Manila Times via GlobeNewswire, with a fresh wire dateline inside the text: "Paris, FRANCE, Aug. 04, 2026" [2]. Same words, new date, nineteen months apart.
The research is real and worth describing precisely. GEG Tech, a Paris biotechnology company, and the Center for Translational Vision Research at UC Irvine, led by Professor Krzysztof Palczewski, used mRNA-delivered base editing to repair the Rpe65 gene in rd12 mice, a model of inherited retinal degeneration [1]. Treated mice recovered more than 50 percent of normal electroretinography function, which the release describes as comparable to the best gene therapy approaches in similar animal models; control mice recovered none [1]. The release contains no human trial data, because there is none to contain.
The science deserves its full due before the correction. Base editing Rpe65 is genuinely promising work on one class of inherited retinal disease, building on a UC Irvine publication from October 2020 that the release itself cites [1]. Palczewski's own quote shows exactly where the frontier sits: "Recent studies have demonstrated the power of our base editing technology to cure genetic retinal diseases in mice models. However, therapeutic and clinical applications will require a scalable, manufacturable, high biosafety vector" [1]. Read the two sentences in order. The word cure lives in the first one, and its patients are mice; the second sentence is a list of what does not exist yet.
"IT WILL CURE BLINDNESS" fails that quote three separate ways. Blindness is not one disease; Rpe65 is one gene and rd12 models one inherited condition. Recovery here is an electrical signal on an ERG readout, not a mouse reading an eye chart, and certainly not a person. The tense is the third failure: will is a promise the release never makes, about trials it does not have, on a timeline nobody states [1].
The freshness came from the wire, not the lab. A newswire re-issue gave a nineteen-month-old release a 2026 dateline; syndication partners like the Manila Times print the date they receive [2]; an aggregation layer reads the syndication date as the news date; a video show reads the aggregation; tens of thousands of viewers receive a January 2025 mouse result as tonight's medical breakthrough. Every node in that chain behaved normally, which is the point: re-syndication is a freshness laundromat that works without any single actor lying. The only patients cured of anything remain the rd12 mice, and that happened at least nineteen months ago.
Verdict: Misleading. The underlying study is real institutional science with a genuinely promising result in mice. Nothing in it supports a future-tense human cure for blindness, its lead researcher's own quote says so in its second sentence, and the January 20th, 2025 dateline means the one thing the video presents as newest, the news itself, is the oldest thing on the screen [1][2].
